BACKGROUND: Retrospective analyses were performed in patients with metastatic renal cell carcinoma (mRCC) to characterise the objective response (OR) rate to sunitinib and differentiate pretreatment features and outcomes of patients with early (response by ⩽ 12weeks) versus late response, and responders versus non-responders.
METHODS: Data were pooled from 1059 patients in six trials. Median progression-free survival (PFS) and overall survival (OS) were estimated by Brookmeyer and Crowley method and compared between groups by log-rank test. Baseline characteristics were compared by Fisher-exact, t-, or Wilcoxon rank-sum tests. Associations between characteristics and survival were investigated by Cox proportional regression analysis.
RESULTS: 398 patients (38%) had confirmed OR (12 complete responses); 26%, 61%, 79% and 86% responded by 6, 12, 18 and 24weeks, respectively. Median (range) time to tumour response (TTR) was 10.6 (2.7-94.4) weeks and was similar in treatment-naïve and cytokine-refractory patients. Median response duration in early and late responders was 52.0 and 55.0 weeks, respectively. Median PFS in early versus late responders was 13.8 versus 20.2months (P=0.001); however, median OS did not significantly differ (37.8 versus 40.8months; P=0.144). Early responders had more lung metastases (P< 0.01), but baseline characteristics were otherwise mostly similar. Median PFS (16.3 versus 5.3months) and OS (40.1 versus 14.5months) were longer in responders versus non-responders (both P< 0.001); responders had more favourable prognostic factors.
CONCLUSIONS: OR occurred in 38% of sunitinib-treated mRCC patients. Sixty-one percent of responses occurred by 12weeks of therapy, and responders had favourable pretreatment features and significantly longer survival.
Written by:
Molina AM, Lin X, Korytowsky B, Matczak E, Lechuga MJ, Wiltshire R, Motzer RJ. Are you the author?
Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA.
Reference: Eur J Cancer. 2013 Sep 16. pii: S0959-8049(13)00789-2.
doi: 10.1016/j.ejca.2013.08.021
PubMed Abstract
PMID: 24051327
UroToday.com Renal Cancer Section
